tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

CNTA Stock Latest News

Centessa Pharmaceuticals’ ORX750: Promising Developments and Buy Rating by David Risinger
RatingsCentessa Pharmaceuticals’ ORX750: Promising Developments and Buy Rating by David Risinger
4d ago
CNTA
Centessa initiated with an Overweight at Piper Sandler
PremiumThe Fly
Centessa initiated with an Overweight at Piper Sandler
12d ago
CNTA
Centessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline
PremiumRatings
Centessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline
12d ago
CNTA
Centessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating
PremiumRatings
Centessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating
16d ago
CNTA
Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating
PremiumRatings
Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating
18d ago
CNTA
Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
PremiumCompany AnnouncementsCentessa Pharmaceuticals Advances OX2R Agonist Pipeline
18d ago
CNTA
Centessa Pharmaceuticals’ ORX750: Promising Phase I Results and Market Potential Justify Buy Rating
Premium
Ratings
Centessa Pharmaceuticals’ ORX750: Promising Phase I Results and Market Potential Justify Buy Rating
19d ago
CNTA
Centessa Pharmaceuticals: Promising OX2R Agonists for Unmet Narcolepsy Needs with Market Expansion Potential
Premium
Ratings
Centessa Pharmaceuticals: Promising OX2R Agonists for Unmet Narcolepsy Needs with Market Expansion Potential
19d ago
CNTA
Centessa reports Q4 EPS (84c), consensus (35c)
PremiumThe Fly
Centessa reports Q4 EPS (84c), consensus (35c)
19d ago
CNTA
Centessa Pharmaceuticals: A Compelling Buy with Promising Orexin Portfolio and Significant Upside Potential
PremiumRatings
Centessa Pharmaceuticals: A Compelling Buy with Promising Orexin Portfolio and Significant Upside Potential
26d ago
CNTA
Centessa assumed with an Overweight at Morgan Stanley
PremiumThe Fly
Centessa assumed with an Overweight at Morgan Stanley
1M ago
CNTA
Centessa Pharmaceuticals Updates on OX2R Agonist Pipeline
PremiumCompany Announcements
Centessa Pharmaceuticals Updates on OX2R Agonist Pipeline
3M ago
8K
CNTA
Centessa appoints Kanes as Chief Medical Officer
PremiumThe FlyCentessa appoints Kanes as Chief Medical Officer
3M ago
CNTA
Centessa initiated with a Buy at TD Cowen
Premium
The Fly
Centessa initiated with a Buy at TD Cowen
3M ago
CNTA
Centessa Pharmaceuticals Secures $200 Million Loan Deal
Premium
Company Announcements
Centessa Pharmaceuticals Secures $200 Million Loan Deal
3M ago
8K
CNTA
Centessa CEO Saha sells 55,000 ordinary shares
PremiumThe Fly
Centessa CEO Saha sells 55,000 ordinary shares
4M ago
CNTA
Centessa management to meet with Oppenheimer
PremiumThe Fly
Centessa management to meet with Oppenheimer
4M ago
CNTA
Centessa price target raised to $28 from $24 at Guggenheim
PremiumThe Fly
Centessa price target raised to $28 from $24 at Guggenheim
5M ago
CNTA
Alkermes price target raised to $31 from $28 at BofA
PremiumThe Fly
Alkermes price target raised to $31 from $28 at BofA
5M ago
ALKS
CNTA
Centessa Pharmaceuticals Strengthens Financial Position Amid Losses
PremiumCompany AnnouncementsCentessa Pharmaceuticals Strengthens Financial Position Amid Losses
5M ago
CNTA
Centessa Pharmaceuticals Advances Pipeline with Promising OX2R Data
Premium
Company Announcements
Centessa Pharmaceuticals Advances Pipeline with Promising OX2R Data
5M ago
8K
CNTA
Centessa reports Q3 EPS (37c), consensus (42c)
Premium
The Fly
Centessa reports Q3 EPS (37c), consensus (42c)
5M ago
CNTA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >